Status: Recruiting
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).
Participants needed: 300
Trial details
Phase: Phase 2Age: Up to 60Biological sex: AllType: InterventionalSponsor: Masonic Cancer Center, University of MinnesotaUpdated: Jun 25, 2026Locations: 1
Eligibility criteria
Age: ≤ 60 years of age [+41]
Chemotherapy refractory large cell and high grade NHL (i.e., progressive disease... [+8]